Payment overview · 2025
General Payments
$672.87
38 reported records · 12 companies
Healthcare provider profile · identity verified
Ryan M Biggers, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MIDWEST CITY, OK · NPI 1194723395
Verified facts
What the public records show
CMS Open Payments records show Ryan M Biggers, M.D. received $672.87 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Nurtec Odt, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.30 | 20.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.49 | 13.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.25 | 10.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.32 | 10.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.04 | 9.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.92 | 8.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.81 | 6.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.97 | 5.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.32 | 5.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.45 | 3.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.67 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.33 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $672.87 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $101.93 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $72.32 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.04 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.04 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.92 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.92 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.71 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.71 | 3 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $45.78 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.78 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.81 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.81 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 130 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 253 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 252 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 49 |
| Gabapentin | Gabapentin | 191 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 50 |
| Lisinopril | Lisinopril | 167 | 45 |
| Omeprazole | Omeprazole | 148 | 39 |
| Montelukast Sodium | Montelukast Sodium | 139 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 134 | 14 |
| Ozempic | Semaglutide | 130 | 23 |
| Losartan Potassium | Losartan Potassium | 119 | 31 |
| Methylprednisolone | Methylprednisolone | 116 | 83 |
| Meloxicam | Meloxicam | 103 | 25 |
| Potassium Chloride | Potassium Chloride | 103 | 31 |
| Metformin Hcl Er | Metformin Hcl | 102 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 25 |
| Prednisone | Prednisone | 93 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 32 |
| Alprazolam | Alprazolam | 88 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 12 |
| Simvastatin | Simvastatin | 86 | 25 |
| Lorazepam | Lorazepam | 82 | 16 |
| Azithromycin | Azithromycin | 80 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 77 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 21 |
| Furosemide | Furosemide | 70 | 26 |
| Famotidine | Famotidine | 68 | 22 |
| Celecoxib | Celecoxib | 63 | 23 |
| Metformin Hcl | Metformin Hcl | 61 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 30 |
| Allopurinol | Allopurinol | 58 | 16 |
| Eszopiclone | Eszopiclone | 58 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 18 |
| Fluconazole | Fluconazole | 53 | 18 |
| Pregabalin | Pregabalin | 52 | 14 |
| Memantine Hcl | Memantine Hcl | 51 | 14 |
| Sertraline Hcl | Sertraline Hcl | 50 | 16 |
| Carvedilol | Carvedilol | 49 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Ezetimibe | Ezetimibe | 48 | 17 |
| Jardiance | Empagliflozin | 45 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 33 |
| Eliquis | Apixaban | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 17 |
| Ondansetron Odt | Ondansetron | 38 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 13 |
| Mupirocin | Mupirocin | 37 | 30 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Zaleplon | Zaleplon | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Nystatin | Nystatin | 33 | 17 |
| Trazodone Hcl | Trazodone Hcl | 33 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 16 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 11 |
| Temazepam | Temazepam | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 16 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Diazepam | Diazepam | 27 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Ramipril | Ramipril | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Gemtesa | Vibegron | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $672.87 · 38 records | ABBVIE INC. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Saxenda, UBRELVY, VIBERZI, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error